20 results about "Histocompatibility" patented technology

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The invention provides a cascade response self-assembly polypeptide for remodeling tumor cell antigen composition, a bioactive solution of the cascade response self-assembly polypeptide and application of the cascade response self-assembly polypeptide. The polypeptide sequentially comprises a hydrophobic end-capping group, an alkaline phosphatase response self-assembly polypeptide sequence, a reduced glutathione response sequence and a T cell epitope peptide sequence. The polypeptide can respond to high-expression alkaline phosphatase in a tumor microenvironment to generate self-assembly and promote efficient internalization of cells; then, the antigen peptide is released under the action of reductive glutathione in tumor cells, and the antigen complex is given to the tumor cells through a main histocompatibility complex I-type molecular antigen presentation pathway. In addition, the specific hydrophobic end-capping group can up-regulate expression of I-type molecules of main histocompatibility complexes of tumor cells, enhance antigen presentation and remarkably enhance the recognition and killing efficiency of antigen-specific T cells on the tumor cells. Combined adoptive immunity and immune checkpoint inhibitor therapy is suitable for combined immunotherapy of solid tumors.

The present invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, specifically a cyclodextrin-based near-infrared fluorescent probe. The near-infrared fluorescent probe is a conjugate in which a fluorescent molecule is encapsulated by cyclodextrin. In the near-infrared fluorescent probe of the present invention, the cyclodextrin is embedded onto a carbon chain of the fluorescent molecule, which improves the water solubility, histocompatibility and safety, enhances the fluorescence lifetime and photostability, and achieves rapid delivery and response in ureters, lymphatic vessels and lymph nodes in vivo. The near-infrared fluorescent probe can be used for NIR-I and NIR-II imaging. In addition, the near-infrared fluorescent probe can be labeled with various tumor-targeting molecules to form targeted near-infrared fluorescent probes, thereby achieving precise targeted fluorescence imaging in both NIR-I and NIR-II windows for different types of tumors such as genitourinary tumors, head and neck cancer, breast cancer and cervical cancer, and metastatic lymph nodes. The near-infrared fluorescent probe can be used for the navigation of fluorescence imaging during clinical surgeries.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present disclosure relates to the identification of single nucleotide polymorphisms (SNPs) in the Gamma genomic block in the central region of the major histocompatibility complex (MHC) that can be used for matching transplant donors and recipients and determining disease susceptibility.

The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to granulocyte precursor cell that has been differentiated in vitro, wherein the granulocyte precursor cell comprises: (a) increased expression of one or more of: serglycin (SRGN), myeloperoxidase (MPO), major histocompatibility complex, class II, DR alpha (HLA-DRA), CD74, and elastase (ELANE) when compared to an equivalent granulocyte precursor cell that has been differentiated in vivo; and / or (b) decreased expression of one or more of: defensin alpha 1 (DEFA1), defensin alpha 3 (DEFA3), cathelicidin antimicrobial peptide (CAMP), bactericidal permeability increasing protein (BPI), and azurocidin 1 (AZU1) when compared to an equivalent granulocyte precursor cell that has been differentiated in vivo. Also provided are cells, methods for producing the same, uses of the same, and kits comprising the same.

The invention discloses a transcription template DNA (Deoxyribose Nucleic Acid) of an LMP1 (Lipoprotein Protein 1) antigen mRNA (Messenger Ribonucleic Acid) and the LMP1 antigen mRNA obtained by transcription of the transcription template DNA. The transcription template DNA is formed by sequentially connecting a promoter, a 5'end non-coding region, a human tissue plasminogen activator gene secretion signal peptide, an LMP1 antigen coding region, a main histocompatibility complex I-type transport signal, a 3 'end non-coding region, a poly (adenylic acid) tail and a terminal sequence; the human tissue plasminogen activator gene secretion signal peptide, the LMP1 antigen coding region and the main histocompatibility complex type I transport signal are connected through a GS flexible linker. The LMP1 antigen mRNA disclosed by the invention efficiently expresses the LMP1 antigen and induces specific immune response in a body. The invention also discloses an application of the LMP1 antigen mRNA in preparation of drugs for preventing and / or treating EBV-related tumors.

The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide / MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and method for making and using the same.

Systems and methods for t-cell receptor complex optimization using quantum variational autoencoders. Mixed-state t-cell receptor (TCR) embeddings and mixedstate major histocompatibility complex peptide (pMHC) embeddings can be generated (110) by embedding input TCR sequences and input pMHC sequences, respectively, using a quantum variational autoencoder (QVAE). A combinatorial optimization of the mixed-state TCR embeddings while fixing the mixed-state pMHC embeddings can be performed (120) using a machine learning-based predictor. TCR sequences from the mixed-state TCR embeddings and the mixed-state pMHC embeddings, after the combinatorial optimization, can be decoded (130) using the QVAE to generate an optimized TCR sequence. The optimized TCR sequence can be synthesized (140) as a synthetic compound for downstream tasks.

This invention provides an active polypeptide and its application in the preparation of drugs that promote the repair of endometrial damage, belonging to the field of biomedical technology. The sequence of the polypeptide is as follows: Acetyl-Gly-Phe-Phe-Tyr-Gly-Val-Arg-Lys-Lys-Pro. The active polypeptide of this invention is non-cytotoxic and non-reproductive toxic, and can promote the proliferation of endometrial epithelial cells, restore the number of endometrial glands in cases of intrauterine adhesions, reduce the proportion of fibrosis, and promote the thickening of thin endometrium. Its effects are superior to PDGF protein, and it has advantages such as high tissue compatibility, simple preparation, and significant improvement effects.

This invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica. More specifically, this invention relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods for preparing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica.

The invention provides a biomarker for pathological staging judgment of primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises a peroxisome bifunctional enzyme, phosphoenolpyruvate carboxykinase, a receptor expression enhancing protein 6, an HLA (human leukocyte antigen) II histocompatibility antigen gamma chain and a C-X-C motif chemotactic factor 10. According to the method, the improvement of the PBC diagnosis efficiency is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive PBC pathological staging judgment method is provided, and a theoretical basis is provided for early diagnosis of PBC.

Provided herein are methods and systems for phenotype-agnostic isolation of antigen-specific T cells using the ATTACH assay (Assessment of T cells Tethered to Antigen Class I / II Histocompatibility). Also provided are antigen-specific T cells isolated using the ATTACH assay and methods of their use for treatment of a subject.

Provided is a cell having improved tissue compatibility with a transplantation subject. Specifically, by knocking a polynucleotide encoding a single-chain fusion peptide that mimics HLA-G and / or HLA-E that has an inhibitory effect on the activity (cell damage) of NK cells and macrophages into a region encoding the alpha chain of an HLA class I molecule, it is possible to inhibit the expression of the alpha chain of the HLA class I molecule while expressing the single-chain fusion peptide.

The invention discloses a pMHC binding agent and application thereof. The antigen peptide-major histocompatibility complex binding agent comprises four RNA molecules, wherein the first RNA molecule comprises an antigen peptide, a DRB1 * 13: 02 beta chain, a mouse I-Eb binding segment and nucleic acid molecules coded by CD28 and CD3 zeta proteins of transmembrane and intracellular segments; the second RNA molecule comprises CMV, CD74, an antigen peptide and a nucleic acid molecule coded by a red visible spectrum fluorescent protein; the third RNA molecule comprises CD4 and a nucleic acid molecule coded by a T cell surface receptor binding region peptide sequence; and the fourth RNA molecule comprises mCD40L and a nucleic acid molecule coded by a binding peptide fragment for recognizing pMHC. According to the present invention, the antigen peptide-major histocompatibility complex II type molecule and the T cell surface receptor can be efficiently and specifically combined so as to promote the activation of the target cell surface receptor so as to achieve the efficient autoimmune reaction;

The invention relates to the technical field of biomedical materials, in particular to a skin wound and mucous membrane repairing composition using an exosome vesicle delivery technology and a preparation method and application thereof.The skin wound and mucous membrane repairing composition is prepared from, by weight, 25-35 parts of glycerinum, 5-9 parts of sodium hyaluronate, 3-7 parts of tetrahydromethylpyrimidine carboxylic acid, 1-3 parts of 1, 3-butanediol, 1-3 parts of 1, 3-butanediol, 1-3 parts of 1, 3-butanediol, 1-3 parts of 1, 3-butanediol, 1-3 parts of 1, 3-butanediol, 1 The exosome is prepared from the following components in parts by weight: 3-7 parts of 1, 2-hexanediol, 3-7 parts of p-hydroxyacetophenone, 3-5 parts of carbomer, 2-4 parts of sophocarpidine, 0.5-1.5 parts of arginine, 25-35 parts of exosome, 8-12 parts of crithmum maritimum callus culture filtrate, 15-25 parts of provitamin B5 and the balance of purified water. The exosome is used as a core repair component, has good compatibility with humanized tissue, can be rapidly absorbed by damaged tissue, and can regulate inflammatory response, promote cell proliferation and differentiation and accelerate wound healing by releasing active molecules; meanwhile, under the synergistic effect of components such as crithmum maritimum callus culture filtrate and provitamin B5, the repairing effect is further improved, and wound surface or mucosa repairing is facilitated.

This present disclosure relates to immunology, particularly methods of predicting whether a therapeutic protein is likely to trigger an immunogenic response. An example method for predicting an amino acid-immunoprotein complex (IPC) interaction may comprise: accessing a set of amino acid sequences; accessing an immunoprotein complex (IPC) sequence identified for an IPC of a subject; processing a set of amino acid sequence representations to generate a set of transformed amino acid sequence representations based on a set of element-focused scores representing binding cores of the set of amino acid sequence representations; processing an IPC sequence representation to generate a transformed IPC sequence representation; generating composite representations; and determining one or more predicted amino acid-IPC interactions based on the composite representations.

The application discloses a traditional Chinese medicine hydrogel composition for preventing and treating postoperative wound infection of anorectum, a preparation method and application thereof, and is based on a classic Chinese medicine plaster, combined with clinical experience, and is formed by optimizing a traditional Chinese medicine compound preparation, and is wrapped by using glycerol as a wrapping agent, to form a stable temperature-sensitive in-situ hydrogel drug delivery system, so that the traditional Chinese medicine preparation is combined with the hydrogel, and problems existing in traditional plasters are effectively solved. The traditional Chinese medicine hydrogel composition directly acts on a wound, has good adhesion and histocompatibility, can prolong the residence time of the drug in a medication site, and improves the bioavailability; effective components of the traditional Chinese medicine compound preparation prevent the formation of a bacterial biofilm on a postoperative wound of anorectum, and inhibit wound infection; the hydrogel dosage form forms a moist protective film on the postoperative wound, forms a microenvironment conducive to wound healing, thereby accelerating healing, promoting recovery, effectively alleviating the pain of patients, and having important medical value.